Cargando…
BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer
BACKGROUND: Mutations in BRCA1 and BRCA2 are associated with better survival in ovarian cancer (OC) patients due to a better response to platinum-based chemotherapy. However, the impact of the BRCA1/2 mRNA-expression is not well characterized in OC. PATIENTS AND METHODS: We investigated BRCA1/2 mRNA...
Autores principales: | Tsibulak, Irina, Wieser, Verena, Degasper, Christine, Shivalingaiah, Giridhar, Wenzel, Sören, Sprung, Susanne, Lax, Sigurd F., Marth, Christian, Fiegl, Heidelinde, Zeimet, Alain G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173779/ https://www.ncbi.nlm.nih.gov/pubmed/30111871 http://dx.doi.org/10.1038/s41416-018-0217-4 |
Ejemplares similares
-
BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer
por: Wieser, Verena, et al.
Publicado: (2018) -
The miR-34 family and its clinical significance in ovarian cancer
por: Welponer, Hannah, et al.
Publicado: (2020) -
Clinical Impact of RANK Signalling in Ovarian Cancer
por: Wieser, Verena, et al.
Publicado: (2019) -
Tumor necrosis factor receptor modulator spermatogenesis‐associated protein 2 is a novel predictor of outcome in ovarian cancer
por: Wieser, Verena, et al.
Publicado: (2019) -
Clinical impact of EZH2 and its antagonist SMARCA4 in ovarian cancer
por: Leitner, Katharina, et al.
Publicado: (2020)